TABLE OF CONTENTS
1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET 53
1.4 LIMITATIONS 54
1.5 MARKETS COVERED 55
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET: GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 CURRENCY AND PRICING 62
2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.7 DBMR VENDOR SHARE ANALYSIS 67
2.8 MULTIVARIATE MODELING 69
2.9 PRODUCTS LIFELINE CURVE 69
2.10 SECONDARY SOURCES 70
2.11 ASSUMPTIONS 70
3 MARKET OVERVIEW 71
3.1 DRIVERS 73
3.1.1 INCREASING GERIATRIC FEMALE POPULATION 73
3.1.2 INCREASING NUMBER OF INFECTIOUS AND CHRONIC DISEASES 74
3.1.3 INCREASING INVESTMENTS IN THE RESEARCH AND DEVELOPMENTAL ACTIVITIES 75
3.1.4 GROWING NUMBER OF DIAGNOSTIC DEVICE MANUFACTURING COMPANIES 76
3.2 RESTRAINTS 77
3.2.1 PRODUCT RECALLS OF VARIOUS COMPANIES 77
3.2.2 HIGH COST OF DIAGNOSTIC PRODUCTS 78
3.3 OPPORTUNITIES 79
3.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE DIAGNOSTIC EQUIPMENT 79
3.3.2 STRATEGIC INITIATIVES BY VARIOUS COMPANIES 80
3.4 CHALLENGES 81
3.4.1 UNACCEPTABLE HEALTH DISPARITIES IN THE U.S. 81
3.4.2 PRICING PRESSURE 81
3.4.3 INCREASING ADOPTION OF REFURBISHED DIAGNOSTIC IMAGING SYSTEMS 82
4 EXECUTIVE SUMMARY 83
5 PREMIUM INSIGHTS 85
6 GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET, BY DIAGNOSTIC DEVICES 88
6.1 OVERVIEW 89
6.2 IMAGING AND MONITORING SYSTEMS 90
6.2.1 MAMMOGRAPHY SYSTEMS 90
6.2.1.1 DEVICES 90
6.2.1.1.1 DIGITAL MAMMOGRAPHY SYSTEMS 91
6.2.1.1.2 BREAST TOMOSYNTHESIS 91
6.2.1.1.3 ANALOG MAMMOGRAPHY SYSTEMS 91
6.2.1.2 APPLICATIONS 91
6.2.1.2.1 BREAST LUMPS OR TUMORS 92
6.2.1.2.2 BREAST CANCER 92
6.2.1.2.3 OTHERS 92
6.2.2 ULTRASOUND IMAGING SYSTEMS 92
6.2.2.1 DEVICES 92
6.2.2.1.1 OB/GYN ULTRASOUND 92
6.2.2.1.2 BREAST ULTRASOUND 92
6.2.2.2 APPLICATIONS 93
6.2.2.2.1 PREGNANCY SCAN 93
6.2.2.2.1.1 FETAL DEVELOPMENT 93
6.2.2.2.1.2 FETAL ABNORMALITIES 93
6.2.2.2.1.3 OTHERS 94
6.2.2.2.2 PELVIC SCAN 94
6.2.2.2.2.1 ABNORMAL PERIODS 94
6.2.2.2.2.2 CYSTS 94
6.2.2.2.2.3 FIBROIDS 94
6.2.2.2.2.4 OTHERS 94
6.2.2.2.3 ABDOMINAL SCAN 95
6.2.2.2.4 OTHERS 95
6.2.2.2.4.1 BREAST SCANS 95
6.2.2.2.4.2 MUSCULOSKELETAL SCANS 95
6.2.2.2.4.3 INTERNAL STRUCTURES 95
6.2.3 MRI SYSTEMS 95
6.2.3.1 APPLICATIONS 96
6.2.3.1.1 BREAST SCAN 96
6.2.3.1.2 ABDOMEN SCAN 96
6.2.3.1.3 JOINTS SCAN 96
6.2.3.1.4 SPINAL CORD SCAN 96
6.2.3.1.5 CARDIAC SCAN 96
6.2.3.1.6 BLOOD VESSELS SCAN 97
6.2.3.1.7 OTHERS 97
6.2.4 FERTILITY MONITORS 97
6.2.4.1 APPLICATIONS 97
6.2.4.1.1 OVULATION 97
6.2.4.1.2 INFERTILITY 97
6.2.4.1.3 PREGNANCY 97
6.2.4.1.4 HORMONAL IMBALANCE 98
6.2.4.1.5 OTHERS 98
6.2.5 BONE DENSITOMETER 98
6.2.5.1 APPLICATIONS 98
6.2.5.1.1 OSTEOPOROSIS 98
6.2.5.1.2 BONE-RELATED PROBLEMS 98
6.2.5.1.3 RHEUMATOID ARTHRITIS 98
6.2.6 NUCLEAR IMAGING SYSTEMS 99
6.2.6.1 APPLICATIONS 99
6.2.6.1.1 OSTEOARTHRITIS 99
6.2.6.1.2 HEART DISEASE 99
6.2.6.1.3 UROLOGICAL PROBLEMS 100
6.2.6.1.4 GYNECOLOGICAL CANCERS 100
6.2.6.1.5 MULTIPLE SCLEROSIS 100
6.2.6.1.6 ALZHEIMER'S DISEASE 100
6.2.6.1.7 THYROID DISEASE 100
6.2.6.1.8 SEXUALLY TRANSMITTED INFECTIONS 100
6.2.6.1.9 STROKE 100
6.2.6.1.10 POST-TRAUMATIC STRESS DISORDER (PTSD) 100
6.2.6.1.11 LUPUS 100
6.2.6.1.12 OTHERS 101
6.2.7 OTHERS 101
6.3 BIOPSY DEVICES 101
6.3.1 BIOPSY FOR CANCER 102
6.3.1.1 BREAST CANCER 102
6.3.1.2 CERVICAL CANCER 102
6.3.1.3 OVARIAN CANCER 102
6.3.1.4 OTHERS 102
6.3.2 BREAST LUMPS BIOPSY 102
6.3.3 BLOOD BIOPSY 103
6.3.3.1 CANCEROUS 103
6.3.3.2 NON-CANCEROUS 103
6.3.4 LYMPH NODES BIOPSY 103
6.3.5 THYROID BIOPSY 103
6.3.6 SKIN BIOPSY 103
6.3.7 OTHERS 104
6.4 REAGENTS AND KITS 104
6.4.1 PREGNANCY AND FERTILITY TESTING KITS 105
6.4.1.1 PREGNANCY 105
6.4.1.2 OVULATION 105
6.4.1.3 OTHERS 105
6.4.2 BLOOD TEST TYPE KIT 105
6.4.2.1 OSTEOPOROSIS 106
6.4.2.2 BLOOD CHEMISTRY & BLOOD CELL COUNT 106
6.4.2.3 OTHERS 106
6.4.3 HEPATITIS TESTING KIT 106
6.4.4 TUMOR MARKER ELISA TEST KIT 106
6.4.5 STD TEST KITS 106
6.4.5.1 HIV TESTING 107
6.4.5.2 HUMAN PAPILLOMAVIRUS (HPV) TESTING 107
6.4.5.3 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TESTING 107
6.4.5.4 OTHERS 107
6.4.6 PAP SMEAR TEST KIT 107
6.4.7 MRSA TESTING KITS 107
6.4.8 HORMONE MARKERS ELISA KITS 107
6.4.9 TUBERCULOSIS TEST KIT 107
6.4.10 OTHERS 107
6.5 BIOMARKERS 108
6.5.1 ONCOLOGY 108
6.5.1.1 BREAST CANCER 109
6.5.1.2 CERVICAL CANCER 109
6.5.1.3 OVARIAN CANCER 109
6.5.1.4 OTHERS 109
6.5.2 PREGNANCY COMPLICATIONS 109
6.5.3 INFECTIOUS DISEASES 109
6.5.4 CARDIOVASCULAR DISEASES 109
6.5.5 OTHERS 109
6.6 OTHERS 110
7 GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET, BY END USER 111
7.1 OVERVIEW 112
7.2 HOSPITALS 113
7.3 DIAGNOSTIC AND IMAGING CENTERS 113
7.4 CLINICS 114
7.5 HOME CARE SETTING 114
8 GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET, BY GEOGRAPHY 115
8.1 OVERVIEW 116
8.2 NORTH AMERICA 121
8.2.1 U.S. 132
8.2.2 CANADA 141
8.2.3 MEXICO 150
8.3 EUROPE 159
8.3.1 GERMANY 171
8.3.2 FRANCE 180
8.3.3 U.K. 189
8.3.4 ITALY 198
8.3.5 SPAIN 207
8.3.6 RUSSIA 216
8.3.7 SWITZERLAND 225
8.3.8 NETHERLANDS 234
8.3.9 BELGIUM 243
8.3.10 TURKEY 252
8.3.11 REST OF EUROPE 261
8.4 ASIA-PACIFIC 262
8.4.1 JAPAN 274
8.4.2 CHINA 283
8.4.3 INDIA 292
8.4.4 AUSTRALIA 301
8.4.5 SOUTH KOREA 310
8.4.6 THAILAND 319
8.4.7 SINGAPORE 328
8.4.8 MALAYSIA 337
8.4.9 INDONESIA 346
8.4.10 PHILIPPINES 355
8.4.11 REST OF ASIA-PACIFIC 363
8.5 SOUTH AMERICA 364
8.5.1 BRAZIL 375
8.5.2 REST OF SOUTH AMERICA 382
8.6 MIDDLE EAST & AFRICA 383
8.6.1 SOUTH AFRICA 394
8.6.2 REST OF MIDDLE EAST AND AFRICA 401
?
9 GLOBAL BIOPSY DEVICES IN WOMEN'S HEALTH DIAGNOSTICS MARKET, COMPANY LANDSCAPE 402
9.1 COMPANY SHARE ANALYSIS: GLOBAL 402
9.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 403
9.3 COMPANY SHARE ANALYSIS: EUROPE 404
9.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 405
10 GLOBAL MAMMOGRAPHY SYSTEM IN WOMEN'S HEALTH DIAGNOSTICS MARKET, COMPANY LANDSCAPE 406
10.1 COMPANY SHARE ANALYSIS: GLOBAL 406
10.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 407
10.3 COMPANY SHARE ANALYSIS: EUROPE 408
10.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 409
11 GLOBAL ULTRASONIC IMAGING SYSTEM IN WOMEN'S HEALTH DIAGNOSTICS MARKET, COMPANY LANDSCAPE 410
11.1 COMPANY SHARE ANALYSIS: GLOBAL 410
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 411
11.3 COMPANY SHARE ANALYSIS: EUROPE 412
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 413
12 GLOBAL MRI SYSTEM IN WOMEN'S HEALTH DIAGNOSTICS MARKET, COMPANY LANDSCAPE 414
12.1 COMPANY SHARE ANALYSIS: GLOBAL 414
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 415
12.3 COMPANY SHARE ANALYSIS: EUROPE 416
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 417
13 COMPANY PROFILE 418
13.1 HOLOGIC INC 418
13.1.1 COMPANY SNAPSHOT 418
13.1.2 REVENUE ANALYSIS 419
13.1.3 COMPANY SHARE ANALYSIS 419
13.1.4 PRODUCT PORTFOLIO 419
13.1.5 RECENT DEVELOPMENTS 420
13.2 SIEMENS 421
13.2.1 COMPANY SNAPSHOT 421
13.2.2 REVENUE ANALYSIS 422
13.2.3 COMPANY SHARE ANALYSIS 422
13.2.4 PRODUCT PORTFOLIO 422
13.2.5 RECENT DEVELOPMENTS 430
13.3 GENERAL ELECTRIC 431
13.3.1 COMPANY SNAPSHOT 431
13.3.2 REVENUE ANALYSIS 432
13.3.3 COMPANY SHARE ANALYSIS 432
13.3.4 PRODUCT PORTFOLIO 432
13.3.5 RECENT DEVELOPMENT 435
13.4 KONINKLIJKE PHILIPS N.V. 435
13.4.1 COMPANY SNAPSHOT 435
13.4.2 REVENUE ANALYSIS 436
13.4.3 COMPANY SHARE ANALYSIS 436
13.4.4 PRODUCT PORTFOLIO 436
13.4.5 RECENT DEVELOPMENTS 440
13.5 HITACHI, LTD. 441
13.5.1 COMPANY SNAPSHOT 441
13.5.2 REVENUE ANALYSIS 442
13.5.3 COMPANY SHARE ANALYSIS 442
13.5.4 PRODUCT PORTFOLIO 442
13.5.5 RECENT DEVELOPMENTS 445
13.6 FUJIFILM HOLDINGS CORPORATION 445
13.6.1 COMPANY SNAPSHOT 445
13.6.2 REVENUE ANALYSIS 446
13.6.3 COMPANY SHARE ANALYSIS 446
13.6.4 PRODUCT PORTFOLIO 446
13.6.5 RECENT DEVELOPMENTS 449
13.7 ABBOTT 449
13.7.1 COMPANY SNAPSHOT 449
13.7.2 REVENUE ANALYSIS 450
13.7.3 PRODUCT PORTFOLIO 450
13.7.4 RECENT DEVELOPMENTS 452
13.8 BD 452
13.8.1 COMPANY SNAPSHOT 452
13.8.2 REVENUE ANALYSIS 453
13.8.3 PRODUCT PORTFOLIO 454
13.8.4 RECENT DEVELOPMENTS 455
13.9 BIOMERIEUX SA 455
13.9.1 COMPANY SNAPSHOT 455
13.9.2 REVENUE ANALYSIS 456
13.9.3 PRODUCT PORTFOLIO 456
13.9.4 RECENT DEVELOPMENT 456
13.10 BIOMERIEUX SA 458
13.10.1 COMPANY SNAPSHOT 458
13.10.2 REVENUE ANALYSIS 458
13.10.3 PRODUCT PORTFOLIO 459
13.10.4 RECENT DEVELOPMENT 459
13.11 CANON INC. 460
13.11.1 COMPANY SNAPSHOT 460
13.11.2 REVENUE ANALYSIS 460
13.11.3 PRODUCT PORTFOLIO 461
13.11.4 RECENT DEVELOPMENTS 462
13.12 CARDINAL HEALTH 463
13.12.1 COMPANY SNAPSHOT 463
13.12.2 REVENUE ANALYSIS 463
13.12.3 PRODUCT PORTFOLIO 464
13.12.4 RECENT DEVELOPMENT 465
13.13 CARESTREAM HEALTH 466
13.13.1 COMPANY SNAPSHOT 466
13.13.2 PRODUCT PORTFOLIO 466
13.13.3 RECENT DEVELOPMENT 467
13.14 COOK 468
13.14.1 COMPANY SNAPSHOT 468
13.14.2 DIVISION PORTFOLIO 468
13.14.3 RECENT DEVELOPMENTS 469
13.15 DANAHER 470
13.15.1 COMPANY SNAPSHOT 470
13.15.2 REVENUE ANALYSIS 470
13.15.3 PRODUCT PORTFOLIO 471
13.15.4 RECENT DEVELOPMENTS 472
13.16 F. HOFFMANN-LA ROCHE LTD. 473
13.16.1 COMPANY SNAPSHOT 473
13.16.2 REVENUE ANALYSIS 473
13.16.3 PRODUCT PORTFOLIO 474
13.16.4 RECENT DEVELOPMENTS 476
13.17 MEDGYN PRODUCTS, INC 477
13.17.1 COMPANY SNAPSHOT 477
13.17.2 PRODUCT PORTFOLIO 477
13.17.3 RECENT DEVELOPMENT 478
?
13.18 NEUROLOGICA CORP. 479
13.18.1 COMPANY SNAPSHOT 479
13.18.2 PRODUCT PORTFOLIO 479
13.18.3 RECENT DEVELOPMENTS 482
13.19 PERKINELMER INC. 483
13.19.1 COMPANY SNAPSHOT 483
13.19.2 REVENUE ANALYSIS 483
13.19.3 PRODUCT PORTFOLIO 484
13.19.4 RECENT DEVELOPMENT 485
13.20 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 486
13.20.1 COMPANY SNAPSHOT 486
13.20.2 PRODUCT PORTFOLIO 486
13.20.3 RECENT DEVELOPMENTS 487
13.21 SHIMADZU CORPORATION 488
13.21.1 COMPANY SNAPSHOT 488
13.21.2 REVENUE ANALYSIS 488
13.21.3 PRODUCT PORTFOLIO 489
13.21.4 RECENT DEVELOPEMNT 490
13.22 SYSMEX CORPORATION 492
13.22.1 COMPANY SNAPSHOT 492
13.22.2 REVENUE ANALYSIS 492
13.22.3 PRODUCT PORTFOLIO 493
13.22.4 RECENT DEVELOPMENT 493
13.23 THERMO FISHER SCIENTIFIC INC. 494
13.23.1 COMPANY SNAPSHOT 494
13.23.2 REVENUE ANALYSIS 494
13.23.3 PRODUCT PORTFOLIO 495
13.23.4 RECENT DEVELOPMENTS 495
13.24 URIT MEDICAL ELECTRONIC CO., LTD 496
13.24.1 COMPANY SNAPSHOT 496
13.24.2 PRODUCT PORTFOLIO 496
13.24.3 RECENT DEVELOPMENT 497
?
14 CONCLUSION 498
15 SWOT ANALYSIS AND DBMR ANALYSIS 499
15.1 SWOT ANALYSIS 499
15.2 DATA BRIDGE MARKET RESEARCH ANALYSIS 501
16 QUESTIONNAIRE 502
17 RELATED REPORTS 507